SVCM
KALV

Saturn V Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Saturn V Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,793
Closed -$710K – 20
2025
Q2 		$710K Sell
62,793
-192,267
-75% -$2.35M 0.29% 23
2025
Q1 		$2.94M Sell
255,060
-301,429
-54% -$3.08M 1.49% 17
2024
Q4 		$4.71M Hold
556,489
– – 1.85% 16
2024
Q3 		$6.44M Sell
556,489
-571,989
-51% -$7.19M 2.3% 17
2024
Q2 		$13.3M Sell
1,128,478
-313,474
-22% -$3.66M 5.02% 10
2024
Q1 		$17.1M Sell
1,441,952
-365,611
-20% -$4.87M 6.86% 4
2023
Q4 		$22.1M Sell
1,807,563
-2,683
-0.1% -$24.4K 8.48% 3
2023
Q3 		$17.4M Buy
1,810,246
+397,910
+28% +$4.07M 7.3% 2
2023
Q2 		$12.7M Buy
1,412,336
+290,354
+26% +$2.68M 7.05% 6
2023
Q1 		$8.82M Buy
1,121,982
+402,045
+56% +$3M 6.59% 9
2022
Q4 		$6.7M Buy
+719,937
New +$3.86M 5.56% 11

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Saturn V Capital Management's KALV Position: Q3 2025 in Review

Saturn V Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 62,793 shares — an estimated $710K sold.

Saturn V Capital Management first reported a position in KALV in Q4 2022 and held it in 11 quarters. The position peaked at $22.1M in Q4 2023. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • Saturn V Capital Management reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 62,793 KalVista Pharmaceuticals shares in Q3 2025, an estimated $710K.
  • Saturn V Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • Saturn V Capital Management's KalVista Pharmaceuticals position peaked at $22.1M in Q4 2023.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.